Vancomycin & Other Cell-Wall Agents
When the β-lactams fail and MRSA is loose in the bloodstream, one old, difficult drug is often the answer — vancomycin, so large and awkward it can't even squeeze into Gram-negative bacteria, and so easily mistaken for an allergy that it turns patients red. Understanding it, and its membrane-punching cousin daptomycin, completes the story of drugs that attack the bacterial envelope.
A patient with a serious bloodstream infection is deteriorating, and the lab confirms the worst: MRSA — a Staph aureus that has changed its PBP so that no β-lactam can touch it. The penicillins and cephalosporins are useless here. So the team hangs a slow infusion of vancomycin. As it drips in too fast at first, the patient's face and neck flush bright red and itchy — but this isn't an allergy, and slowing the drip fixes it. Vancomycin is awkward, toxic, and irreplaceable, and every quirk it has teaches something.
A different way to wreck the wall
Vancomycin blocks the wall's building blocks, not the enzyme. Vancomycin, a glycopeptide, also inhibits cell-wall synthesis, but by a completely different route from the β-lactams. Instead of blocking the PBP enzyme, it grabs the wall's building block itself — the D-Ala-D-Ala end of the peptidoglycan precursor — so the material can't be added to the growing wall. Because it's a big, bulky molecule, it can only reach the wall of Gram-positive bacteria; it simply can't cross the outer membrane of Gram-negatives, so it has no Gram-negative activity at all. Its role is therefore specific and vital: serious Gram-positive infections, above all MRSA and other resistant staphylococci and streptococci.
The quirks that matter
Vancomycin is a demanding drug. Infused too quickly, it triggers a histamine release that flushes the upper body red and itchy — the 'red person syndrome,' which is NOT a true allergy and is prevented simply by slowing the infusion. It can also harm the kidneys and, less often, the ears, so its blood levels are monitored to stay in a safe, effective range. Given by mouth it isn't absorbed at all — which turns out to be useful: oral vancomycin stays in the gut and is a first-line treatment for Clostridioides difficile colitis, working right where that infection lives. Resistance does exist (vancomycin-resistant enterococci, VRE, which swap the D-Ala-D-Ala target for D-Ala-D-Lac so the drug can't bind), a reminder that even the drug of last resort is not immune.
Daptomycin and the rest
A few other drugs attack the bacterial envelope. Daptomycin is a lipopeptide that punches into the Gram-positive cell membrane (not the wall), rapidly depolarizing and killing it — a valuable alternative for MRSA and even VRE. Its famous caveat: it's inactivated by lung surfactant, so it must NEVER be used for pneumonia. It can also raise muscle enzymes, so CK is monitored. Beyond these, bacitracin is too toxic for the body and survives only as a topical agent, and fosfomycin blocks an early step of wall building and is handy as a single oral dose for simple urinary infections. Together, these complete the picture: whether by blocking the enzyme, seizing the building block, or breaching the membrane, all these drugs bring the bacterium down by attacking its envelope.
- Vancomycin (glycopeptide) binds D-Ala-D-Ala to block wall synthesis — a different mechanism from β-lactams.
- Gram-positive ONLY (too big for the Gram-negative outer membrane); key drug for MRSA.
- Red person syndrome = fast-infusion histamine release, NOT allergy — slow the drip.
- Oral vancomycin isn't absorbed → first-line for C. difficile colitis; watch nephro/ototoxicity (monitor levels).
- Daptomycin (membrane) treats MRSA/VRE but is inactivated by surfactant — never for pneumonia.
The same drug, given two ways, treats two completely different things — because vancomycin isn't absorbed from the gut. Given intravenously, it circulates and treats MRSA in the blood and tissues but does nothing for a gut infection (it never reaches high levels there). Given ORALLY, it does the opposite: it stays trapped in the intestine, useless for a bloodstream infection but perfect for killing C. difficile right in the bowel. Route completely changes what the drug can treat — a vivid lesson straight from pharmacokinetics.
- Treating red person syndrome as an allergy and abandoning vancomycin. Just slow the infusion.
- Using vancomycin for a Gram-negative infection. It can't reach them at all.
- Giving IV vancomycin for C. difficile colitis. Use ORAL vancomycin, which stays in the gut.
- Using daptomycin for pneumonia. Lung surfactant inactivates it.
A patient develops upper-body flushing and itching during a rapid vancomycin infusion. This is:
- Vancomycin binds D-Ala-D-Ala to block wall synthesis; Gram-positive only; key MRSA drug.
- Red person syndrome = infusion-rate histamine release (not allergy); monitor for nephro/ototoxicity.
- Oral (unabsorbed) vancomycin treats C. difficile in the gut; IV treats systemic MRSA.
- Daptomycin (membrane) covers MRSA/VRE but never for pneumonia (surfactant inactivates it).
- Katzung BG. Basic & Clinical Pharmacology — Glycopeptides & other cell-wall/membrane agents.
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Vancomycin, daptomycin & related drugs.
- Rang HP, Dale MM, et al. Rang & Dale's Pharmacology — Glycopeptide antibiotics.
- IDSA guidelines — MRSA treatment; vancomycin therapeutic monitoring; C. difficile therapy.
- Whalen K. Lippincott Illustrated Reviews: Pharmacology — Vancomycin & daptomycin.
